Aspirin Versus Aspirin+Clopidogrel as Antithrombotic Treatment Following TAVI

PHASE4CompletedINTERVENTIONAL
Enrollment

222

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

June 30, 2017

Study Completion Date

March 31, 2018

Conditions
Aortic Valve DiseaseMyocardial InfarctionStrokeBleeding
Interventions
DRUG

Clopidogrel

Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months.

DRUG

Aspirin

Aspirin/acetylsalicylic acid (80-325 mg/d). Aspirin/acetylsalicylic acid therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.

Trial Locations (4)

Unknown

St Michael's Hospital, Toronto

Hospital San Borja Arriaran, Santiago

Hospital Vall d'Hebron de Barcelona, Barcelona

G1V 4G5

Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Québec

All Listed Sponsors
lead

Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec

OTHER

NCT02640794 - Aspirin Versus Aspirin+Clopidogrel as Antithrombotic Treatment Following TAVI | Biotech Hunter | Biotech Hunter